Gilead Sciences, Inc. Share Price

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 24/04/2024 BST 5-day change 1st Jan Change
67.08 USD +0.07% Intraday chart for Gilead Sciences, Inc. +0.22% -17.20%
Sales 2024 * 27.5B 2,207B Sales 2025 * 27.99B 2,246B Capitalization 83.58B 6,706B
Net income 2024 * 2.73B 219B Net income 2025 * 6.88B 552B EV / Sales 2024 * 3.55 x
Net Debt 2024 * 14.01B 1,124B Net Debt 2025 * 8.43B 676B EV / Sales 2025 * 3.29 x
P/E ratio 2024 *
30.1 x
P/E ratio 2025 *
12.2 x
Employees 18,000
Yield 2024 *
4.68%
Yield 2025 *
4.88%
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.07%
1 week+0.22%
Current month-8.42%
1 month-7.58%
3 months-15.65%
6 months-14.17%
Current year-17.20%
More quotes
1 week
65.90
Extreme 65.9
67.68
1 month
65.90
Extreme 65.9
73.87
Current year
65.90
Extreme 65.9
87.87
1 year
65.90
Extreme 65.9
87.87
3 years
57.17
Extreme 57.165
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 28/02/19
Director of Finance/CFO 54 31/12/15
Chief Tech/Sci/R&D Officer - 11/04/21
Members of the board TitleAgeSince
Director/Board Member 69 16/10/20
Director/Board Member 71 31/12/17
Director/Board Member 65 01-31
More insiders
Date Price Change Volume
24/04/24 67.08 +0.07% 8 357 863
23/04/24 67.03 +0.12% 5,240,249
22/04/24 66.95 +0.28% 5,622,367
19/04/24 66.76 +0.91% 10,657,002
18/04/24 66.16 -1.15% 6,442,224

Delayed Quote Nasdaq, April 24, 2024 at 09:00 pm

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
67.03 USD
Average target price
84.95 USD
Spread / Average Target
+26.73%
Consensus